Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12717115 | 0.82 | FFAR4 (0.72) | NOTUMFFAR4CHRM4CHRM2 | |
| SCHEMBL6498392 | 0.81 | NOTUM (0.85) | NOTUMFFAR4CHRM4CHRM2CHRM1 | |
| SCHEMBL2097055 | 0.80 | CHRM4 (0.42) | NOTUMFFAR4CHRM4CHRM2CHRM1 | |
| SCHEMBL18825785 | 0.80 | CHRM2 (0.55) | NOTUMFFAR4CHRM4CHRM2CHRM1 | |
| SCHEMBL12716971 | 0.79 | NEK2 (0.54) | NOTUMCHRM2CHRM1 | |
| SCHEMBL641081 | 0.78 | FFAR4 (0.55) | NOTUMFFAR4CHRM4CHRM2PDK2 | |
| SCHEMBL13896505 | 0.76 | NOTUM (0.53) | NOTUMFFAR4CHRM4PDK2 | |
| SCHEMBL16695371 | 0.74 | NOTUM (0.74) | NOTUMFFAR4CHRM4 | |
| SCHEMBL5799877 | 0.74 | NOTUM (0.60) | NOTUMFFAR4CHRM2PDK2 | |
| SCHEMBL2071701 | 0.74 | NOTUM (0.83) | NOTUMFFAR4CHRM2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615557-B2 | Tetrahydro-naphthalene and urea derivatives | XENTION LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-7615557-B2 | Tetrahydro-naphthalene and urea derivatives | XENTION LIMITED (GB) | 2009-11-10 | — | — | US | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167458-A1 | Tetrahydro-naphthalene and urea derivatives | NQO2, UGT1A4, CYP4B1 | NOTUM 3934/4885FFAR4 2554/4885CHRM4 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.